Craft

Cumberland Pharmaceuticals

Stock Price

$1.2

2024-10-29

Market Capitalization

$17.6 M

2024-10-29

Revenue

$44.5 M

FY, 2025

Cumberland Pharmaceuticals Summary

Company Summary

Overview
Cumberland Pharmaceuticals is a company that focuses on the development and commercialization of prescription products for the hospital acute care and gastroenterology sectors. Its products include Acetadote, an acetylcysteine injection for the treatment of acetaminophen poisoning; Kristalose, lactulose for oral solution; Vaprisol, conivaptan for the treatment of hyponatremia; Sancuso, granisetron transdermal system for chemotherapy treatment; etc.
Type
Public
Status
Active
Founded
1999
HQ
Nashville, TN, US | view all locations
Website
https://www.cumberlandpharma.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • A. J. Kazimi

    A. J. Kazimi, Chairman & Chief Executive Officer

    • Gordon R. Bernard

      Gordon R. Bernard, Director

      • James R. Jones

        James R. Jones, Director

        • James L. Herman

          James L. Herman, Executive Vice President, National Accounts & Chief Compliance Officer

        LocationsView all

        1 location detected

        • Nashville, TN HQ

          United States

          1600 West End Ave #1300

        Cumberland Pharmaceuticals Financials

        Summary Financials

        Revenue (Q1, 2025)
        $9.1M
        Gross profit (Q1, 2025)
        $7.2M
        Net income (Q1, 2025)
        ($3.3M)
        Cash (Q1, 2025)
        $11.0M
        EBIT (Q1, 2025)
        ($3.1M)
        Enterprise value
        $16.7M

        Footer menu